Home » Human Pancreatic Cancer Stem Cell - T75 Plated Cells
Human Pancreatic Cancer Stem Cell - T75 Plated Cells
Catalog Number : 36115-42-T75
Availability : In Stock
Price : $750.00
 

Related Products


  • Description
  • Publication
  • Documents

 Human Pancreatic Cancer Stem Cell - T75 Plated Cells

Also Avaliable as:

Frozen Vial Cells $550.00 shipped with Dry-ice. Cat#36115-45
T25 plated Cells $550.00 shipped at room temperature. Cat#36115-45-T25

120 Population doublings or up to 12 passages.

This product would require pre-coated flasks with Human Pancreatic Cancer Stem Cell Extra-cellular Matrix Cat# E36115-45 and Human Pancreatic Cancer Stem Cell Media Cat# M36115-45

Cell Cultures from single donors, 1000 different cell cultures available, please indicate which lots you require from the 1000 donors, or any subcategories of the cancer type at the time of order.  If you do not specify the subcategory, we will provide you the Human Pancreatic CSC, randomly from our inventory.

Source: Human Pancreatic Cancer tissue

Positive Markers: CD133, CD44, SSEA3/4, Oct4, Tumorigenicity (< 1000 cells), Alkaline Phosphatase, Aldehyde Dehydrogenase, Telomerase, Nestin

For non-academic use, please inquire for pricing.

Cells are only guaranteed with purchase of Celprogen Media and Celprogen Extra Cellular Matrix for appropriate cell culture, for 30 days from the date of shipment.

ELISA Characterization Kits:

CD44 - Human Pancreatic CSC Characterization Kit - Cat# K36115-45A
Nestin - Human Pancreatic CSC Characterization Kit - Cat# K36115-45B
Oct 3/4 - Human Pancreatic CSC Characterization Kit - Cat# K36115-45C
SSEA 3/4 - Human Pancreatic CSC Characterization Kit - Cat# K36115-45D
CD133 - Human Pancreatic CSC Characterization Kit - Cat# K36115-45-E

 

1000 individual donors are fully characterized proprietary patient-derived xenografts (PDX) representing all major histotypes and capturing tumor diversity.

Subcutaneous, orthotopic and disseminated models.  Extensive molecular and pharmacological characterization as well as information on patients' pretreatment to help you select the most appropriate model.

Integrated approach: use the same PDX models and/or the corresponding cell line in 2D/3D screening assays and follow-up in vivo studies, identify biomarkers predicting tumor sensitivity for your compound.

Individually tailored study designs: proof of concept, dose level and schedule optimization, combinations, biomarker identification, etc.